月度归档 2025年4月26日

Original title of this article: "Does the construction in the middle of the night bring dust rolling? These problems that plague citizens’ lives have been dealt with! 》

Dear friends,

The weekly [Echo] is coming again!

The mixer truck raises dust and the construction noise at night is loud?

Lack of road control, there are great security risks?

The school gate will be flooded whenever it rains, making it difficult to pass?

……

This week’s [Echo]

Continue to solve your problems!

reply

(No.39, 2018)

???

01

User message content

Longxi Mountain, Gaoyao Country Garden, rushed to work day and night, and 2 tons of cars were forbidden to pass through this section. The mixer still shuttled through Cologne Street at 2 or 3 in the morning, raising a lot of dust, and did not sprinkle water on the road to reduce dust, which had a great impact on the life and travel of nearby residents. The dust was rolling during the day and the noise was constant at night. I hope the relevant departments would pay attention to it.

Gaoyao district Committee office

answer

After verification, netizens reported that the situation was true. The construction unit has implemented water spraying and dust removal, but the frequency is not enough, and the dust removal effect is not ideal.

On October 26th, a joint working group was formed by the departments of housing, construction, environmental protection, transportation and traffic police in our district. The person in charge of the Longxi Mountain construction project in Country Garden and the person in charge of the construction unit were interviewed, and the situation reflected by the netizens’ messages was reported to the person in charge. The project construction party was required to strictly abide by various rules and regulations to carry out construction and production according to law, reasonably arrange the construction time, and limit the impact of environmental pollution problems such as dust and noise on the surrounding residents to the greatest extent. It is strictly forbidden to overload and carry vehicles. That night, traffic, traffic police and other departments set up cards around "Country Garden Longxi Mountain" to enforce the law, and rectified the traffic violations of dump trucks, and the rectification action received certain results.

On October 27th, the working group formed a rectification plan on relevant issues as follows:

First, it is forbidden for the construction unit to carry out construction at night (from 22:00 pm to 6:00 am the next day), and the District Housing and Construction Bureau is responsible for supervision. If the construction at night is found, it will be ordered to stop work immediately for rectification.

Second, because the traffic of trucks over 2 tons is restricted in Cologne Street, construction vehicles must bypass the construction site through other roads to avoid dust and noise disturbing people, and the traffic police and transportation departments are responsible for supervision; The District Traffic Police Brigade carries out technical maintenance and upgrade of monitoring equipment in Cologne Street, and the District Transportation Bureau urges the owner to install weighing equipment at the cargo loading site and assign special personnel to manage it.

Third, the construction unit is required to increase the frequency of sprinkling water to reduce the dust on the road section, and the district environmental protection bureau is responsible for supervision.

In the next step, housing, construction, environmental protection, transportation and other departments will establish a linkage mechanism, strengthen joint law enforcement, conduct night inspections, and severely punish violations found. The traffic police department will implement the service system and increase the patrol monitoring of this section by setting up cards and taking irregular measures.

02

User message content

1. On the Hengda Haoting section of Dinghu 321 National Road, even if you can enter the auxiliary road after turning around from west to east, there is no municipal road that can turn into Hengda Haoting. Every day, many people from Duanzhou to Dinghu turn around here and then take the path next to the gas station to enter Hengda Haoting Road. Because it is not a municipal road, the road surface is not maintained and there is no safety control, which has great security risks. It is recommended to improve it!

2. Since the construction of National Highway 321, Xinyuan No.1 Street in Dinghu District has been flooded in every heavy rain, especially when typhoons such as Tiange and Mangosteen arrive, and even the flooding depth is more than 1 meter. The surrounding residents have repeatedly reported their problems to the petition offices and sub-district offices, but they have not received any reply or rectification.

Dinghu district Committee office

answer

(I) About the problem of netizens reflecting the section of Evergrande Haoting.

It is understood that the path that enters Taihe gas station after the U-turn of Hengda Haoting section of National Highway 321 is not a municipal road, but is owned by the gas station. The person in charge of the commercial gas station has no intention to maintain the path at present. Next, our district will strengthen the safety supervision around this section in conjunction with the traffic police department to ensure the travel safety of surrounding residents.

(2) About netizens reflecting the flooding problem in Xinyuan Street.

It is understood that due to the influence of Typhoon Mangosteen No.22 this year, from September 16 to 18, heavy rain continued to fall in our area, with local heavy rain, and the maximum rainfall recorded at Kengkou was 269 mm. Xinyuan First Street was one of the areas where flooding occurred.

During Typhoon Mangosteen, the rainfall lasted for a long time and was heavy, which greatly exceeded the design capacity of urban sewers and drainage standards, making it difficult to drain the rainwater on the pavement in a short time, and flooding occurred in many places in the area to varying degrees. Xinyuan 1st Street mentioned in the letter must be flooded in heavy rain after the construction of National Highway 321. The reason is that the elevation of the road surface has been improved after the urbanization of National Highway 321, which makes Xinyuan 1st Street relatively low-lying and prone to flooding.

In view of this situation, our district will speed up the construction progress of Xinshengtian Canal, complete the project construction as soon as possible under the premise of ensuring the quality, and strive to put it into use as soon as possible, so as to reduce the drainage pressure of urban sewers and reduce the flooding problem during the torrential rain in the district. In addition, the water department of our district has organized the construction team to comprehensively clear the municipal sewers of Xinyuan First Street and surrounding roads to ensure the smooth drainage of sewers in this area. In the next step, our district will refer to the vertical of surrounding roads and other factors, and appropriately adjust the ground elevation of Xinyuan Street to minimize the problem of road surface water accumulation.

03

User message content

1. The road at the gate of xinhua primary school will be flooded whenever it rains, and the water depth is more than 20 centimeters. Primary school students cannot pass after school, so parents need to carry it. I hope the relevant departments will go to the field to investigate and study solutions.

2. Two fans on the Blue Sky Water Gathering Building of Duanzhou Shanghai City Phase II roared for 24 hours. Standing on the balcony, I felt my ears tingle. I didn’t even dare to open the doors and windows at home. I couldn’t sleep when I opened the windows. I have reported to various departments that no one has handled them many times. Blue Sky Shuihui is a clubhouse, which is opened so close to the community. It is not legal at all. A few days ago, I heard the voice of singing K in the middle of the night.

Duanzhou district government office

answer

(1) About the problem that netizens report that the road at the entrance of xinhua primary school will be flooded when it rains.

According to the field investigation, xinhua primary school is located on the land on the east side of Xinghu Avenue and the north side of Donghu Road, which is lower than the municipal roads. The road at the entrance of xinhua primary school belongs to the village road, and drainage pipes and wells have not been built around it. The urban drainage network management center regularly cleans and maintains the municipal drainage pipelines of Xinghu Avenue and Donghu Road to keep the pipelines unblocked. However, due to the lack of supporting drainage facilities and municipal drainage pipelines around xinhua primary school, and the fact that it is located in a low-lying area, rainwater cannot be drained when it rains, so it is easy to form flooding in rainy days. Our district has urged Huanggang Sub-district Office to organize Fenggang West Village to do its best to do the pumping and drainage work of this section in rainy days, and dredge the drainage channels to reduce the impact of stagnant water.

As the north side of xinhua primary school is reserved land for the expansion of Honghu Lake, it will be built by the Municipal Construction Bureau. The next step in this area will be drainage planning and construction together with Honghu Lake, which is transferred to the east. After the drainage network in this area is improved, the flooding problem of the road at the entrance of xinhua primary school can be completely solved.

(B) About the problem that netizens reported that the noise of Shanghai Blue Sky Water Club Phase II disturbed people.

Upon investigation, the name of the place mentioned in the complaint is Duanzhou Blue Sky Holiday Leisure Center (hereinafter referred to as "Blue Sky Shuihui Club") registered in the administrative department for industry and commerce. Duanzhou Sub-bureau of City Comprehensive Law Enforcement Bureau received a report on the disturbance caused by the fan noise of Blue Sky Shuihui Club in early June. After repeated urging by law enforcement officers on June 8, July 11, July 17 and August 6, the club moved two fans on the roof that were originally close to residential buildings to the direction of the road, and connected the extended air ducts of the fans to the sound isolation box, which significantly reduced the noise.

According to the situation reflected by netizens, Duanzhou Branch of the Municipal Comprehensive Law Enforcement Bureau and the District Cultural and Sports Bureau sent law enforcement officers to the scene for mediation. On-site inspection found that in order to reduce noise and avoid noise spread, the club also closed the kitchen window. On the morning of October 10th, law enforcement officers contacted the relevant complainants by telephone to inform them of the handling situation and will monitor the noise of Blue Sky Holiday Leisure Center together with the municipal environmental monitoring station. The complainant expressed satisfaction and understanding of our work.

In the next step, our district will urge Duanzhou Branch of the Municipal Comprehensive Law Enforcement Bureau and the Municipal Environmental Monitoring Station to monitor the noise of the clubhouse as soon as possible, and follow up according to the monitoring report.

04

User message content

The industrial zone on the west side of Xiangang Toll Station often uses night time to secretly discharge harmful waste gas and smoke, which causes people living nearby to have difficulty breathing and seriously affects their health! We have repeatedly complained ineffectively, and now we question whether there is a problem with the efforts of the functional departments to implement the national environmental protection policy.

Gaoyao district government

answer

Recently, the environmental protection bureau of our district has received two complaints about the waste gas pollution in the industrial zone on the west side of the Xian Gang toll station, which the district environmental protection bureau attaches great importance to. Since the beginning of this year, in response to the problem of waste gas pollution in Xiangang Industrial Zone, the District Environmental Protection Bureau has repeatedly conducted surprise inspections with the People’s Government of Xiangang Town on enterprises in the industrial zone, and filed investigations on 14 enterprises with environmental violations, which severely cracked down on environmental violations of enterprises in the region. At the same time, since the creation of our district, the government of Xiangang Town has established a grid system, strengthened supervision and inspection of enterprises in the industrial zone, and required relevant enterprises to implement the environmental management system.

After receiving complaints from the masses, on the evening of October 10, 2018, the law enforcement officers of the District Environmental Protection Bureau, together with the staff of Gaoyao District Environmental Protection Monitoring Station and third-party testing institutions, went to the complaint area to conduct supervision and inspection, and sampled and monitored the ambient air at the northeast side (near the exit of the toll station), south side (in the junior middle school) and west side of the complaint area, and will focus on tracking and inspecting the enterprises near the relevant area according to the results of the ambient air monitoring report.

At the same time, the enterprises involved in waste gas emission and producing at night (Zhaoqing Gaoyao Hongzhan Hardware Plastic Co., Ltd., Chongqing Gaoyao Jinyi Aluminum Co., Ltd., Zhaoqing Gaoyao Zhaoxing Industry and Trade Co., Ltd., etc.) were monitored for waste gas. During the inspection, law enforcement officers found that the exhaust gas collection in the drawing and granulating workshop of Hongzhan Hardware & Plastic Co., Ltd. in Gaoyao District of Zhaoqing City was not perfect and the workshop was irritating, so they immediately asked the company to stop production and rectify. The next day, the district environmental protection bureau issued a notice to the company to stop production and rectify, requiring the company to resume production after the rectification is completed and reported to the bureau for inspection.

In the next step, the District Environmental Protection Bureau will continue to strengthen the supervision and inspection of gas-related enterprises in the industrial zone on the west side of the Xiaogang toll station, and intensify inspections. Once suspected environmental violations are found, they will be seriously investigated and dealt with according to law. At the same time, the district environmental protection monitoring station and third-party testing institutions are required to increase the frequency of spot checks and monitoring of gas-related enterprises near the complaint area, and investigate the enterprises suspected of exceeding the standard discharge according to law.

That’s all for this issue.

If the neighbors have problems to reflect

Then leave us a message ~

Please ask the neighbors to reflect the problems in the [Suggestions] column with evidence and facts, otherwise it will easily lead to a waste of public resources. Thank you for your support!

How to leave a message?

It’s in the "Opinions and Suggestions" column of "Zhaoqing Release"

?

For some netizens’ suggestions with clear views, true information, focusing on a single theme and relative depth, they will be selected separately and submitted to the relevant leaders of the municipal party Committee and municipal government for reference.

To netizens

We will continue to increase the tracking efforts.

Answer your question with [Echo]

At the same time, we will continue to pay attention to the follow-up handling.

Welcome the general public to supervise!

Zhaoqing fafa editorial department

Data collation Cai Tingting

Trainee editor Mo Sha

Editor-in-Chief Tang Qianyu

Editor Zeng Shanjie

Please indicate if the article is reproduced.

From "zhaoqingfabu"

Previous article recommendation

?

?

The incidence of malignant tumor is increasing year by year, which has become a common problem faced by human beings. Traditional treatment methods such as surgery, traditional chemotherapy and radiotherapy have always played a leading role in cancer treatment, but the effects of these treatments are limited. In particular, it is difficult for advanced patients to benefit from these treatments for a long time, nor can they fundamentally solve or change their quality of life. Therefore, researchers are increasingly focusing on the field of immunotherapy. Immunotherapy has brought new opportunities and hopes for the treatment of tumors, among which Immunocheckpoint inhibitors, therapeutic antibodies, tumor vaccines, immunomodulators, adoptive cell therapy, etc. Significantly improved the prognosis of cancer patients, and some patients with advanced cancer obtained long-term survival. In the past two years, many cellular immunotherapy have emerged and developed rapidly, which undoubtedly set off a wave of cancer treatment. So, is cell therapy reliable in treating cancer? In fact, immunotherapy has a history of more than 100 years, and it has only gradually entered the public’s field of vision in the last two years, and it has been absolutely recognized by the world oncology community. 　　

　　

A milestone in the history of cancer immunotherapy In 2013, Science magazine ranked the top ten scientific breakthroughs of the year, and immunotherapy topped the list. In recent years, immunotherapy is one of the hot spots in the research field of tumor treatment at home and abroad, and a large number of clinical studies have shown exciting results. Among them, Cellular immunotherapy uses the self-protection and killing ability of human immune system to achieve anti-tumor effect. Cells with immune function in patients are cultured and proliferated in vitro, and they are given the ability to attack tumor cells by technical means, and then they are imported into patients to realize their own anti-cancer. This therapyAgainst immune cells, not cancer cells.It is not as harmful to the patient’s health as surgery, radiotherapy and chemotherapy. Patients with early cancer can be treated directly, especially with the attack on residual cancer cells after surgery. Judging from the rapid development in scientific research and clinic in recent years, cellular immunotherapy is expected to become the fourth pillar of anticancer therapy in terms of accuracy, effectiveness and safety. Next, the small series of Cancer-free Home gives a general introduction and inventory of a variety of popular and emerging cellular immunotherapy in the biomedical industry, hoping to give cancer friends a general understanding of the general development process of this cancer treatment field.　

0one　　CAR-T cell therapy

CAR-T therapy is chimeric antigen receptor T cell immunotherapy, which is a new precise targeted therapy for treating tumors. T cells are activated by genetic engineering technology, and the positioning navigation device CAR (tumor chimeric antigen receptor) is installed to transform the ordinary "warrior" of T cells into "super warrior" CAR-T cells, Specially identify tumor cells in vivo and kill tumor cells efficiently. So as to achieve the purpose of treating malignant tumors. At present, with 2021, Aquilencel injection, Regioscel injection. It was approved for listing in China, in 2022.Cedarchiorense was approved for listing by FDA.CAR-T therapy is expected to enter the blowout period. Indeed, CAR-T technology has shown good curative effect in many hematological tumors, such as leukemia, lymphoma and multiple myeloma, and more than half of hematologic cancer patients who are on the verge of despair and have no cure have achieved good curative effect. 　

CAR-T cell therapy has been listed at home and abroad at present.

Although the clinical effect of CAR-T therapy on solid tumors is not satisfactory, and it has even been sung down by some people, in recent years, CAR-T therapy has made outstanding progress in the fields of gastric cancer, liver cancer and pancreatic cancer. Scholars at home and abroad have made various modifications to CAR-T, and constantly found new targets for the treatment of various solid tumors. 　 　

Clinical study on CAR-T therapy is out of the loop.

0one Gastric cancer and pancreatic cancer As the first CAR-T cell targeting Claudin18.2 in the world, CT041 emerged as early as the ASCO annual meeting in 2019. At that time, the total objective remission rate was 33.3%, which already surprised the world. Now the more remarkable curative effect is undoubtedly the icing on the cake! This clinical data shows a good treatment prospect for digestive system tumors!

Domestic CAR-T therapy CT041 first appeared in ESMO

Developed by Keji Pharmaceutical at the annual meeting of the European Society of Oncology (ESMO) in 2021.Targeting Claudin18.2(CLDN18.2)Autologous CAR-T candidate productsCT041Showing its presenceDigestive system tumorThe outstanding curative effect can be described as brilliant!

The research data is particularly eye-catching!

1.　All patients’The objective remission rate was 48.6%, and the disease control rate was 73%.All patients with gastric cancerThe total objective remission rate was 57.1%.

2.　Patients with gastric cancer who failed to receive at least 2 lines of treatment in the past:The objective remission rate was 61.1%, and the disease control rate was 83.3%.

3. And the overall tolerance is good!

As of March 3, 2022,CT041 became the first and only CAR-T cell candidate product in the world for the treatment of solid tumors, which entered the confirmatory phase II clinical trial.This is a milestone for CAR-T to conquer the solid tumor field. Congratulations!

In addition, there are many CAR-T cell therapies targeting CLDN18.2.0 2 liver cancer At present, the clinical trial targets of CAR-T in the treatment of liver cancer are mainlyGPC3 (phosphatidylinositol proteoglycan 3). The breakthrough research results completed by Professor Zhai Bo, director of the Department of Tumor Interventions, Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine, were published in the international authoritative journal Clinical Cancer Research on May 5, 2020. By July 24th, 2019, 13 patients had received CAR-GPC3 T cells with a median value of 19.9×108. All the patients are GPC3 positive, and they have received surgical treatment, local treatment or systemic treatment, and they all carry hepatitis B virus (HBV). Two patients achieved partial remission (PR). The 6-month, 1-year and 3-year survival rates of all patients were 50.3%, 42.0% and 10.5% respectively, and the median survival time (OS) was 278 days (39.7 weeks). At the ASCO annual meeting in 2021, Chinese medical researchers published the latest clinical research data of CAR-T drug targeting GPC3 (Ori-CAR-001) in the treatment of recurrent/refractory hepatocellular carcinoma for the first time. As of March 10, 2021, a total of 11 recurrent subjects who received cell infusion were included.All the subjects had advanced hepatocellular carcinoma, and none of them were effective after chemotherapy, TACE (transcatheter arterial chemoembolization) and targeted therapy.Of the 9 evaluable subjects,4 cases achieved partial remission (PR), 3 cases achieved disease stability (SD) and 2 cases developed disease progression (PD).The objective remission rate was 44%, and the disease control rate reached 78%..　

02　　Treatment of tumor infiltrating lymphocytes (TIL)

TILs therapy, simply speaking, is to separate and purify the lymphocytes in the tumor tissue after surgery, select the lymphocytes that can specifically resist cancer, and then amplify and activate them and reinfusion them. This kind of therapy has a history of more than 30 years, and it was first used for malignant melanoma. In recent years, it has given good data in many solid tumors such as cervical cancer and lung cancer.

This therapy is equivalent to pulling back veterans with combat experience directly from the battlefield. After a round of "political review" and "big competition" in professional ability, the spies and traitors are eliminated as far as possible, leaving the ones with the strongest fighting capacity, providing supplies, and then sending them back to the battlefield to continue fighting. Looking at the whole industry, the voice of "innovative therapy based on Tiles cells LN-144 (Lifelecel) is expected to be approved in 2022" is particularly loud. Tiles therapy, as an "ancient" cell therapy, is expected to usher in the first approved product this year, and its great potential in treating solid tumors can not be underestimated, with strong strength and relatively "out of the circle". TILs domain key node event 　 　 In 1982 　

Steven A.Rosenberg and others discovered for the first time that TILs can inhibit the metastasis of melanoma cells in patients.

　 1988 　

The earliest attempt of TILs in clinical treatment: TILs therapy for metastatic melanoma achieved an objective remission rate of 60%.

　 In 2011 　

Steven A.Rosenberg and others published a phase II clinical research data in Clinical Cancer Research: the objective remission rate (ORR) and complete remission rate (CR) of patients with melanoma treated by TILs were 56% and 24% respectively.

　 In 2012 　

Melinda Bachini, a patient with advanced intrahepatic cholangiocarcinoma, is called the first patient to achieve complete remission (CR) after TILs therapy.

　 2019 　

At the ASCO meeting, the clinical results of innovative therapies LN-145 and LN-144(Lifileucel) based on TILS cells in the treatment of cervical cancer and melanoma have attracted wide attention in the medical field.FDA awarded LN-145 breakthrough therapy recognition.

　 In 2021 　

Phase I clinical results of TILs cell therapy at AACR meeting: among 12 evaluable patients.Non-small cell lung cancer patientsMedium,TIL therapy can achieve a total remission rate of 25%, among whichTwo patients achieved lasting complete remission.

　 In 2021 　

At the annual meeting of tumor immunotherapy association (SITC), the clinical research results of LN-145 in the treatment of metastatic non-small cell lung cancer (mNSCLC) showed that in 28 cases,In patients with recurrent/refractory mNSCLC,After LN-145 monotherapy,The overall remission rate (ORR) was 21.4%(1 case of CR and 5 cases of PR, including 2 cases of PD-L1 negative tumors), 12 cases were stable, and the disease control rate (DCR) was 64.3%.

03　　TCR-T therapy

CAR-T cells and TCR-T cells belong to T cells modified by genetic engineering technology.Compared with CAR-T therapy, TCR-T therapy has unique advantages in the field of solid tumor treatment. TCR-T cell therapy can identify tumor-specific antigens from cell membrane surface or intracellular sources, and has entered clinical application from the initial basic immune research, showing initial efficacy in solid tumors, and has become the most likely T cell immunotherapy to make a breakthrough in the field of solid tumors!　

1、 TCR-T cell therapy in China has been approved for clinical use and has become a potential new therapy for HBV-related hepatocellular carcinoma!

At present, in addition to the global TCR-T in full swing in the research and development and clinical verification stage, China is also constantly breaking through innovation.

On December 22nd, 2021, CDE (Drug Evaluation Center) official website was able to inquire about the clinical application of "SCG101 Autologous T Cell Injection", which is a TCR-T cell therapy for specific hepatitis B virus (HBV) epitopes and a potential new therapy for HBV-related hepatocellular carcinoma (HCC).

▲ Image source: CDE official website

2、 Advanced liver cancer ushered in a new dawn! TCR-T therapy makes cancer patients completely relieved.

As early as 2020 International Hepatology Conference (ILC), ADP-A2AFP, a new TCR-T therapy for liver cancer based on T cells, caused quite a stir, and also made a new breakthrough in the new therapy for liver cancer.

Among the included patients,One patient showed a complete remission (CR) in cancer progression, and the AFP of the other participants also decreased to varying degrees.This means that the experiment has made progress, and it also shows that this therapy is effective for the treatment of advanced liver cancer.

　 　 　 　 　 　 　

All the 9 patients involved had undergone surgery and conventional radiotherapy and chemotherapy, but failed or became intolerant. Among the 4 patients who received the highest dose of treatment,One patient achieved complete remission, and CT scan showed that all the lesions in the patient disappeared, and it has lasted for more than half a year without any recurrence!

The best response of other patients (cohort 1, cohort 2) is stable. 1 patient in queue 2After one month of treatment, the volume of the primary lesion did not decrease, but the volume of mediastinal lymph node metastasis decreased obviously!　 　 　 　

Therefore, TCR-T therapy targeting AFP (alpha-fetoprotein) can kill tumor cells expressing AFP. Based on the positive results of this study, researchers are expected to expand the maximum dose to 5 billion cells, and we look forward to the publication of updated data of this study!

04　　CAR-NK therapy

In recent two years, in addition to CAR-T therapy, another new cancer cell therapy- Natural killer (NK) cell therapy It has also gradually attracted attention. The researchers said, NK cell As a cell anticancer therapy, it has more potential, and it may be safer, cheaper and faster. CAR-NK is to add a chimeric antibody to NK cells by genetic engineering that can recognize tumor cells and activate NK cells to kill tumor cells at the same time.　

one 　 The first "spot" CAR-NK clinical trial in China was approved by the Food and Drug Administration. On November 11, 2021, National Medical Products Administration Drug Evaluation Center passed an independent research and development in China. Mesothelin (MSLN) chimeric antigen receptor NK cells (CAR-NK) injection for the treatment of advanced epithelial ovarian cancer. Application for clinical trial of CAR-NK injection. According to the cancer-free home, This product is the first "spot" CAR-NK product of foreign origin in China. This also marks a new milestone in the research of immune cell drugs in the treatment of solid tumors in China!　

2　　The 1-year survival rate doubled, and the curative effect of CAR-NK therapy in solid tumor increased sharply.

Recently, the journal Clinical Oncology Research published a phase II clinical trial for lung cancer. Heat shock protein 70(Hsp70) is highly expressed in about 70% of middle and advanced lung cancer. NK cells are activated by Hsp70 in vitro, which is equivalent to making NK cells meet their future enemies in vitro, "making enemies" first, and then returning them to patients, so that NK cells can formally fight with cancer cells in vivo. This method of stimulating NK cells with antigen peptides in vitro and giving them certain specificity is a hot topic in recent years.

A total of 16 patients with stage III non-small cell lung cancer were enrolled in this clinical trial. One group received traditional chemotherapy combined with radiotherapy and chemotherapy, and the other group received chemotherapy combined with Hsp70 pre-stimulated NK cell reinfusion.

The results show that:The one-year survival rate can be doubled from 33% to 67% by Hsp70 pre-stimulated NK cell reinfusion therapy combined with traditional radiotherapy and chemotherapy, and the preliminary results are encouraging.

Next, Xiaobian shows a typical successful case in combination therapy, as shown in the figure:After 1~2 months of treatment, the lung tumor completely disappeared and the curative effect has been maintained for 18 months.

　 　　

In addition to the above-mentioned clinical studies at home and abroad, CAR-NK cells also have a good effect on glioblastoma and neuroblastoma, specifically recognizing and killing breast cancer cells with high efficiency, and have a remarkable effect on multiple myeloma.

05　　Dendritic cell vaccine

Cancer vaccine is a form of immunotherapy, which can prevent cancer from developing or kill existing tumors by stimulating or restoring the human immune system. Dendritic cell (DC) vaccine is a new biological therapy for malignant tumor in recent years, which has been paid more and more attention and recognized by oncologists. As an important member of the human immune defense system, Dendritic cells have the strongest antigen presenting function and are known as "sentinels" of the immune system. It is named because its cells extend outward with many dendritic protrusions. It mainly uses modern high-tech biotechnology to collect the peripheral blood of tumor patients, induce and cultivate a large number of dendritic cells in a short time in vitro, and equip them with immune cells that patients do not have, so as to accurately "target" and kill cancer cells. Not only that, It can also induce immune memory in patients, so that patients can obtain long-term anti-cancer effect.

DCVAC/LuCa is a dendritic cell vaccine developed by the United States for patients with non-small cell lung cancer.In a study on the first-line treatment of advanced lung cancer announced at the ASCO conference in 2019, DCVAC/LuCa vaccine combined with chemotherapy groupThe objective remission rate is 45%,The median overall survival time was 15.5 months, and the median progression-free survival time was 6.74 months.Reduce the risk of death by 46%!

In the Phase II clinical study of the latest novel dendritic cell vaccine DCVAC/LuCa (lung cancer dendritic cell vaccine) combined with standard carboplatin/pemetrexed in the treatment of advanced non-squamous cell (nsq) non-small cell lung cancer in 2022,The 1-year survival rate was 72.73% and the 2-year survival rate was 52.57%.By the time the data was published, the median overall survival time had not been reached. The median progression-free survival time was 8.0 months, and the objective remission rate was 31.82%.

　 Prostate cancer-Provenge vaccine 　

Provenge is the first vaccine approved for treatment in the United States, which initiated a new era of cancer immunotherapy.This is an autologous cell immunotherapy, which was approved by FDA on April 29, 2010 to treat asymptomatic or mild mCRPC. This approval marks the success of 20 years of unremitting efforts.In the United States, Provenge is the only FDA-approved immunotherapy for prostate cancer made from patients’ own immune cells.

　 Ovarian cancer-dcvac/ovca vaccine 　

At the 50th annual meeting of the Society of Gynecological Oncology (SGO) in 2019, the final result of SOV02, a phase II clinical trial, was announced: DCVAC/OvCa, an immunotherapy based on dendritic cells, was added to standard carboplatin and gemcitabine schemes for patients with recurrent, platinum-sensitive and epithelial ovarian cancer.It can prolong the overall survival (OS) of patients with advanced recurrent ovarian cancer by more than one year.andDCVAC/OvCa reduced the death risk of second-line treatment of ovarian cancer by 62%. The overall survival (OS) increased significantly by 13.4 months. The median progression-free survival rate (mPFS) increased by 1.8 months. The global phase III study will be launched soon.

Melanoma-TLPLDC vaccine

The subgroup analysis results of the phase IIb clinical trial of TLPLDC vaccine in the treatment of melanoma were published at the ASCO-SITC Clinical Immunooncology Conference in 2020.

In that population analysis follow the clinical research protocol (PT), compared with the comfort unit,The 24-month disease-free survival rate in TLPLDC treatment group was significantly improved (62.9% vs 34.8%), indicating that the relative risk of disease recurrence was reduced by nearly 50%.

In the population analysis of Intentional Treatment (ITT),There was no significant improvement in 24-month disease-free survival between TLPLDC treatment group and placebo group (38.5%)　vs　27%），But in this analysis,The improvement trend of 24-month overall survival rate (OS) was stronger (86.4% vs 75.1%)..

　 Kidney Cancer-Ilixadencel Vaccine 　

Ilixadencel is an allogeneic dendritic cell (DC) vaccine. Research shows that,Ilixadencel combined with targeted anticancer drug sunitinib(Sotan, common name: sunitinib)First-line treatment of newly diagnosed advanced metastatic renal cell carcinoma（mRCC）Compared with patients treated with sunitinib alone, the total remission rate is doubled, the complete remission rate is higher and the remission is more lasting!

　 Glioblastoma-AV-GBM-1 vaccine 　 On June 8, 2021, well-known foreign biomedical companies announced the release of phase II clinical trial data of their personalized cancer vaccine AV-GBM-1. The research shows that this new vaccine has great potential for prolonging the overall survival of newly diagnosed glioblastoma patients in the medium term. The median progression-free survival time of patients was 10.4 months, which was about 50% higher than the median progression-free survival time of 6.9 months in the landmark STUPP study, and established a nursing standard for newly diagnosed glioblastoma patients. 　 　 Non-small cell lung cancer-tedopi vaccine 　

On April 1st, 2020, a new anti-cancer vaccine, TEDPI, achieved positive results in the phase III clinical trial of non-small cell lung cancer. After the immune checkpoint inhibitor (PD-1) was resistant or failed, all patients in the group used TEDPI vaccine in the second or third line, and the overall survival rate for one year reached 46%, far exceeding the preset 25%!

A 54-year-old patient with advanced lung cancer has rapidly shrunk (from 39mm to 23mm) after five injections of the new lung cancer vaccine. At the time of reporting, his survival time has exceeded 20.6 months, and he is still being followed up.

06　　CIK cell therapy

　 CIK cells, that is, Cytokine-Induced Killer (CIK), are a new type of immunocompetent cells, which have strong proliferative ability and cytotoxicity, and have certain immune characteristics. Because this cell expresses both CD3 and CD56 membrane protein molecules, it is also called NK cell (natural killer cell)-like T lymphocyte, which has both the strong anti-tumor activity of T lymphocyte and the non-MHC-limited anti-tumor advantage of NK cell. If NK cells are the "first line of defense" to protect human health, then CIK cells are undoubtedly the "precision missiles" to kill tumor cells. Especially for patients after surgery or radiotherapy and chemotherapy, it can eliminate residual tiny metastatic lesions, prevent cancer cells from spreading and recurring, and improve immunity. Therefore, CIK cells are considered as the first choice for a new generation of adoptive cellular immunotherapy for tumors. Research progress of representative CIK cell therapy 　 　　

nasal pharyngeal cancer 　

Among 137 patients with nasopharyngeal carcinoma treated by CIK, 50% of them improved their survival time by 6-9 months, and among 137 patients treated by CIK, 50% of them delayed their tumor progression by 6-7 months.

　 liver cancer 　

Among the 819 patients with liver cancer treated by CIK, 50% of them improved their survival time by 13~25 months, and among the 819 patients treated by CIK, 50% of them delayed their tumor progression by 4~7 months.

　 ovarian cancer 　

Among 72 patients with ovarian cancer treated by CIK, 50% of them have improved their survival time by 24 months. Among 72 cases of ovarian cancer treated by CIK, 50% of ovarian cancer patients delayed their tumor progression by 14.5 months.

　

carcinoma of colon

Among 126 patients with colon cancer treated by CIK, 50% of them have a longer survival time of 30 months. Among 126 patients with colon cancer treated by CIK, 50% of them delayed their tumor progression by 14.5 months.

　 breast cancer 　

The probability that the survival time of 150 breast cancer patients treated with CIK can reach 5 years is increased to 85.7%; The probability of keeping breast cancer from recurring in 150 breast cancer patients treated with CIK within 5 years increased to 72.3%.

　 Solid tumor 　

Of the 31 patients treated with PD-1 antibody combined with DC-CIK, 2 patients’ tumors completely subsided and 5 patients’ tumors partially subsided. Of the above 7 patients, 6 patients’ effects can be maintained for 5 months. The tumors of the other 13 patients remained stable.

　 renal carcinoma 　

Among 43 patients with advanced renal cell carcinoma treated by CIK, 50% of them can delay the tumor progression to 14.7 months.

07　　CAR-M therapy　

In recent years, the study of macrophages has also been paid attention to by the industry. How to activate the anti-tumor activity of these macrophages is the direction that immunologists have been working hard. CD47, an immune checkpoint on macrophages, has become a very promising hot target in the field of tumor immunotherapy.

In a recent study published in Nature Biotechnology, researchers from perelman Medical College of the University of Pennsylvania and other research institutions may have an alternative to T cell therapy to overcome these challenges. Their research shows that genetic modification of macrophages (an immune cell that devours intruders in vivo) may be the key to developing effective cell therapy for solid tumors. They were able to confirm these genetically modified expressions. The macrophages of CAR (CAR-M) can kill tumors in human samples and mouse models in the laboratory and prolong their life.　 　

　　

CAR-M therapy is centered on macrophages, which devour invading cells instead of destroying them like T cells. T cells are more like Space Invaders games, while macrophages are more like Pac-Man games. Another major difference between macrophages and T cells is that they are the first responders of the body to virus infection. Historically, this poses a challenge in trying to genetically modify them to attack cancer, because macrophages are not easily transfected by standard viral vectors used in gene therapy and cell therapy.

In this experiment, the research team used genetic engineering technology to transform macrophages. They not only expressed CAR targeting HER2 antigen, but also were activated and differentiated into M1 macrophage types that promoted inflammation. In this way,These CAR-M cells can not only target tumor cells, but also change the microenvironment near tumors by secreting pro-inflammatory cytokines. They can also present tumor antigens to T cells and activate T cells’ immune response to tumors, which can be described as "killing three birds with one stone".

On March 18th, 2021, Carisma Company of the United States announced the completion of the first drug delivery to the subjects of CAR-M therapy (CT-0508) targeting Her2, marking a new era of CAR-M transformation therapy for solid tumors. In a word, taking macrophages as effector cells transformed by CAR is expected to reverse the tumor inhibitory microenvironment, so as to break through the obstacles of immune cell therapy in solid tumors.　

08　　CTL (cytotoxic T lymphocyte) therapy

What cell therapy can be used as an adjuvant therapy for the majority of patients with inoperable advanced cancer? In recent years, researchers have been developing new immunotherapy schemes for these patients, including CTL(cytotoxic T lymphocytes) technology. This technology mainly uses protein, which is unique to cancer cells and has no or low content in normal cells, as bait to select the truly anticancer lymphocytes in peripheral blood, and then further improve and amplify them in vitro, and then return them to patients. MTCA-CTL immunotherapy is a new generation of biological immunotherapy model introduced in China. While ensuring the expansion of non-MHC-restricted killer NK-T cells, directional expansion of HC-restricted CD8＋+specific CTL cells can make its proportion in cell products reach 60% ~ 70%. The combined effect of this killer cell makes the efficiency of killing tumor cells higher. 　

At present, the multi-target compound antigen peptide biological immunotherapy technology, which is undergoing the second phase of clinical trials in the Cancer Hospital of China Academy of Medical Sciences, is the fifth and brand-new generation of cellular immunotherapy technology, which can optimize the activation method of DC (dendritic cells) to enhance the killing effect of immune cells on tumor cells. At present, it has achieved good clinical results and I believe it will really benefit cancer patients.

【Mainly suitable for solid tumors.】Head and neck tumor, esophageal cancer, lung cancer, gastric cancer, breast cancer, liver cancer, membranous adenocarcinoma, colorectal cancer, ovarian cancer, uterine cancer, coma cancer, prostate cancer, malignant melanoma, sarcoma and partial malignant lymphoma.

If economic conditions permit and you want to consult MTCA-CTL therapy, you can contact.Cancer-free Home Medical Department (400-626-9916), a detailed assessment of the condition.

09　　CAR-NKT therapy

　 Natural killer T cells (NKT) are a group of special T cell subsets that express both T cell receptors (TCR) and NK cell receptors on the cell surface, and can produce a large number of cytokines. Such as IL-4 and INFγ. These cells can not only directly dissolve and kill tumor cells, but also play an anti-tumor role through indirect ways (secreted cytokines, activated immune cells, etc.). Recently, a phase I clinical trial jointly conducted by Baylor Medical College in Houston and Texas Children’s Hospital is evaluating a new treatment for children with recurrent neuroblastoma –CAR-NKT cell therapy is expected to break through this bottleneck. Phase I trial, code-named GINAKIT2, used CAR-NKT cells for the first time to treat recurrent neuroblastoma. Eleven children (1~21 years old, with an average age of 7 years old) were all recurrent/refractory high-risk neuroblastoma, with extensive metastasis and no better treatment plan in clinic. The results are very encouraging: Of the 11 advanced patients, The condition of 4 patients was stable, 2 patients achieved partial remission (tumor was obviously reduced), and one of them had complete remission (CR) after receiving the second CAR-NKT cell infusion. In safety, CAR-NKT is safer than CAR-T therapy. No dose-limiting toxicity was observed in the first 28 days after infusion.　

10　　Compound immune cell therapy

This technology will alsoSix kinds of cells, such as γδT cells, NK cells, NKT cells, killer T cells, dendritic cells and helper T cells.Activate, multiply 10 million to 20 million cells to 2 billion to 5 billion cells, and then inject them into patients. Cultivating such important immune cells at the same time greatly improves the therapeutic effect compared with single treatment.

Except for some leukemia and malignant lymphoma,It can be used for the treatment of most cancers, and has a good effect in refractory cancer types and advanced cancers. Besides,Compound immune cells also play a great role in improving immunity and strengthening the body.

Xiaobian has something to say

In recent years, due to the development of medical level, new cancer treatment methods have appeared one after another, among which cellular immunotherapy is in full swing, which brings new hope to cancer patients. According to the latest statistics, compared with patients with advanced lung cancer, gastric cancer and liver cancer who only receive surgery, radiotherapy and chemotherapy, adjuvant cellular immunotherapy can prolong the survival time of patients and significantly improve the data effect. In fact, tumor treatment is actually a complex "project", and it is difficult to achieve good results by relying solely on a certain treatment method. Tumor treatment needs the cooperation of various treatment methods to achieve the final victory in the fight against cancer.　

Hinako Sakurai starred in the Japanese TV series Bathing Girl.

People’s Daily Online, Tokyo, July 1st According to the report of Japanese channel comprehensive Japanese fashion entertainment website Modelpress, the Japanese drama "Bathing Girl" will be broadcast on July 15th in the Japanese drama Paravi column of Tokyo TV Station, which will be broadcast at 12: 58 every Wednesday night, starring actress Hinako Sakurai.

The drama tells the story of a female white-collar worker who loves to take a bath at home, Hayashi Nobuyoko, challenging all kinds of bathing methods, looking for "what is the best bathing method" and showing a bathing-centered lifestyle.

Now, influenced by the COVID-19 epidemic, the whole country advocates a new way of life, and the time for people to stay in their own homes is bound to increase. This drama is a series that can be operated in such a home time, with the theme of enjoying a bath. The play is adapted from the comic book of the same name of Shan Hao, which was serialized in the Weekly Big-comics Spirits from 2015 to 2016, and published three volumes of singles. It is a new comic book with the theme of bathing experience.

Sakurai plays the hero, Hayashi Nobuyoko. This is the first time Sakurai has appeared and starred in a TV series of Tokyo TV. Sakurai, who has read the original work, said: "I feel the same way about the comic book, and there are new discoveries. This work expands the possibility of taking a bath and is very interesting. Now because of the COVID-19 epidemic, everyone is looking for a reasonable way to use home time. I think this work is undoubtedly a very meaningful work. "

Screenwriters are Yosuke Masachi, who has been in charge of many late-night TV dramas of Tokyo TV, such as Renting People Who Do Nothing, Death Camp, and Yukori Nakamura, who has written TV dramas such as Metropolitan Police Department Search for a Section Chief and Nepenthes Dream. Directed by Jun’ichi Ishikawa, his main works include TV series Legal High, FRAGILE, movies April Fool’s Day, Love Swing and so on.

The play will premiere exclusively on the video website "Paravi". (Compile: Xue Yixiang Proofreading: Chen Jianjun) (Source:Modelpress)

(Copyright statement: This article is the content of the Japanese entertainment fashion website Modelpress exclusively authorized by People’s Daily Japan Channel. It is forbidden for any organization to use the content and pictures of the article in any form, including but not limited to reprinting and adaptation. )

Recently, the 3D animation "Double Pride", adapted from Gu Long’s classic martial arts IP, presents the story of the twin chivalrous brothers "Little Fish and Hua Wuque" to the audience again with exquisite production and beautiful painting style, which awakens everyone’s memory and longing for the children in the Jianghu who are dressed in fresh clothes and brave in chivalry. On October 3rd, the animation of "Double Pride" rushed into the top ten of Tencent Animation Channel, which triggered a heated discussion among the audience. Many viewers praised it for its "authentic martial arts flavor of Gu Long" and "modeling intentions and aesthetic online". The popularity of "Double Pride" shows that animation, a popular expression for young audiences, is an effective way to spread martial arts culture and inherit chivalrous spirit.

Animated interpretation of Gu Long’s classic IP, innovative transmission of the chivalrous spirit of the East

As a leading writer of martial arts novels, Gu Long has created 57 works with more than 25 million words in his life. These works have created a series of chivalrous figures in the Jianghu, such as Xiaoyu, Hua Wuque, Li Xunhuan and Shen Lang, which convey the core of multiple chivalrous spirits such as "friendship, belief and transcendence". "Two Prides in a Family", which began to be serialized in 1966, is a masterpiece among them, and has been adapted into film and television works for many times, which is very popular among the audience.

The animated version of "Double Pride" mainly tells the story that Xiaoyu and Hua Wuque started their Jianghu trips from the Villain’s Valley and the Flower Palace respectively, and in the process, they never met each other and went to appreciate each other, and then joined forces to fight against the villains. The tortuous and bizarre life experience adds a "sad" background to the fate of the two brothers who were forced to separate since childhood. Because of this, the two people showed their indomitable and unyielding qualities in their respective growth processes, such as "getting out of the mud without being stained", which moved countless audiences.

In the animation, the two brothers joined hands with the heroine Tie Xinlan to fight against the five villains, the twelve astrologers and the villain Jiang Yulang. The wisdom, courage, sense of justice and the trust and mutual support between their peers are very suitable for the current context, full of praise for the truth, goodness and beauty of human nature and whipping the false, evil and ugly, which is of value guiding significance to young audiences.

As the first animated work in Gu Long’s martial arts IP, "Double Pride" also inherits the martial arts culture well — — This unique cultural element and valuable asset of China. For a long time, no matter how the external environment changes, Chinese people have always maintained a high degree of reverence and praise for chivalrous spirits such as gratitude, honesty and trustworthiness, once upon a time in america, etc., and thus many literary and film works have been born, constantly conveying the feelings and righteousness, kindness and warmth in the world. It can be said that "chivalrous spirit" has become one of the unique cultural business cards of the Chinese nation.

The new era needs new works and new expressions. How to make young people understand and love China’s traditional culture has always been a big problem in the process of literary and artistic creation. Especially with the development of the times, young people’s appreciation ability and aesthetic demand for literary and artistic works are increasing day by day. Only by constantly innovating expression forms on the basis of ensuring the content can we better attract the audience. The animation "Double Pride" not only restores all kinds of strange people in the rivers and lakes in Gu Long’s works, but also shows a strong antique charm and romantic atmosphere in scene modeling, painting style, soundtrack and action design. For example, the elegant and refined Flower Transfer Palace, the sinister villain’s valley and the magnificent Murong Mountain Villa are beautifully and freehand restored in the film, showing an all-encompassing river and lake scene; In addition, the title also presents the "Great War Seventeen Years ago" in the form of ink painting to the audience, highlighting the "romance and lofty sentiments" of Gulong Jianghu in all directions.

To sum up, With the help of 3D animation, a literary form popular with young audiences, "Two Prides in a Family" gives a vivid and vivid secondary image to the mysterious wonders of rivers and lakes and strange people with unique skills. At the same time, it also vividly displays many emotions such as friendship, affection, love and chivalry, so that the audience can gain a brand-new aesthetic experience while being subtly influenced by China’s traditional martial arts culture and spirit.

Martial arts culture links non-legacy handicrafts to make national culture glow with new vitality.

On November 21st, the animation of "Two Prides in a Family" joined hands with the national key non-legacy project "Wang’s Shadow Play in Huaxian County" to launch the activity of "The Swordsman’s Shadow Play resurfaces", and at the same time exposed the shadow play handicraft works of Xiaoyuer and Hua Wuque, in which Hua Wuque was armed with a long sword, wore a hairpin, dressed in blue, tied with a jade pendant and a fragrant bag, and the image of a gentle and elegant son came to the fore. The little fish holds a short knife in each hand, dressed in red cloth, tied with a rope and a bag around his waist, with weeds in his mouth and unruly eyes, and his lively and agile image temperament is also vivid; In addition, the overall line design of these two shadow puppetry works is also very fine. The lines and patterns on the clothes of Xiaoyuer and Hua Wuque are very clear, vivid and have ancient charm. Once they were launched, they won praise from the audience.

Shadow play originated in the Western Han Dynasty more than 2,000 years ago and originated in Shaanxi Province, China. In Huazhou District, Weinan City, Shaanxi Province, the hometown of shadow play in China, Wang Haiyan, the non-genetic inheritor of Wang’s shadow play, has been committed to the combination and promotion of national culture and intangible heritage for many years, and has designed many exquisite and heritage-rich handicraft works for various cultural products, including movies, cartoons and games. This time, the dream linkage between "Wang’s Shadow Play" and the animation "Two Prides in a Family" has brought the shadow play, a cultural heritage with a long history and tradition, back to the public in a younger and more dynamic way, bringing the audience beautiful enjoyment and conveying the value and charm of intangible culture to the young audience.

At the same time, martial arts culture, like shadow play, belongs to Chinese treasures, and classics need to be passed down. In this activity, the swordsman spirit carried in the classic IP of "Two Prides in a Family" was presented in a more vivid and diverse way in the combined narrative of "animation+shadow play", and the shadow play handicraft works with multiple artistic values such as aesthetics and collection were produced, which were welcomed by young audiences. This is of great significance for young audiences to feel the charm of Chinese culture and enhance their cultural self-confidence and cultural identity.

To sum up, as a Guo Man’s work adapted from the classic martial arts IP, it has both sentimental and cultural heritage value. In the cross-dimensional cooperation of "animation+martial arts", "Double Pride" shows its unique charm and is well received by young audiences, which provides a good example for how contemporary literary works can make young people better understand and accept traditional culture. (Author: Zhang Jianzhen, deputy director of Radio, Film and Television Research Center, Institute of Journalism and Communication, China Academy of Social Sciences)

China Art Newspaper (2nd edition, November 21st, 2022)

China Network April 17 (Reporter Zhang Yanling) Health is an inevitable requirement to promote people’s all-round development, and it is also an important symbol of national prosperity and national prosperity. With the rapid development of economy, society and human civilization, health has become the first demand of the people after China has built a well-off society and solved the problem of food and clothing. The CPC Central Committee attaches great importance to scientific and technological innovation and puts forward that science and technology should "face people’s lives and health".

On April 15th, 2023 China Medical Development Conference was held in Beijing.

Medical science and technology is closely related to people’s health and social well-being, and it is a key factor to promote human health. In order to better serve people’s lives and health, medical science and technology must be innovated, and innovation needs to create a good ecology. So, how to create a good ecology of medical science and technology innovation? On April 15th, at the 2023 China Medical Development Conference held by China Academy of Medical Sciences, the participants discussed the construction of national medical science and technology innovation system and the strategy of creating a good ecology.

Chen Zhu, vice-chairman of the Standing Committee of the 13th National People’s Congress, president of China Red Cross Society and academician of China Academy of Sciences, believes that we should focus on helping to build a healthy China, improving people’s health and well-being, identify the frontiers of medical health science and technology, actively explore the road of new medical education reform, promote the transformation of discipline layout, resource allocation and scientific research ecology, build a good innovative ecology, and make overall plans for innovative layout, so as to contribute wisdom to accelerating the construction of a healthy China and building a healthy human community.

Wang Zhizhen, vice chairman of the 11th Chinese People’s Political Consultative Conference, member of China Academy of Medical Sciences and academician of China Academy of Sciences, believes that the medical science and technology circles in China should be based on the national conditions, take the strategy of healthy China as the guide, dare to challenge the "subversive" problem, accelerate the exploration of the development path of the national modern medical science and technology innovation system, and make innovative contributions to the national medical development.

To create a good ecology of medical science and technology innovation, it is necessary to strengthen supervision. Jiao Hong, member of the 14th Chinese People’s Political Consultative Conference Standing Committee, vice chairman of the 17th Central Committee of the Agricultural Workers’ Party and director of the National Medical Products Administration, believes that entering a new stage of development, it is necessary to benchmark the world’s scientific and technological frontier, strengthen internationally advanced regulatory scientific research, and promote the modernization of drug regulatory system and regulatory capacity, so as to contribute to the high-quality development of China’s pharmaceutical industry and better protect people’s drug safety and health.

Wang Chen, vice president of China Academy of Engineering, academician of China Academy of Engineering, president of China Academy of Medical Sciences, and chairman of academic advisory committee of China Academy of Medical Sciences, believes that to create an innovative ecology of medical science and technology, we should pay attention to "four core elements", namely, academic culture, institutional system, capital resources and international environment, which are finally reflected in the subject of innovation-"people". Therefore, it is necessary to inherit the culture of medical science and technology innovation, improve the system of medical science and technology innovation, establish the mechanism of medical science and technology innovation, expand the resources of medical science and technology innovation, and create an ecological environment of medical science and technology innovation.

Wang Chen said that to create a good medical science and technology innovation ecology, we must establish a good scientific order and value orientation, strengthen academic, scientific and technological cultural construction, and build a scientific medical science and technology evaluation system; Increase investment in innovation in the field of medical health and set up a national medical health science fund as soon as possible; It is necessary to cultivate the innovation ecosystem of clinical and translational medicine and improve the scientific and technological innovation ability of hospitals.

At the same time, it is necessary to strengthen the national medical strategic scientific and technological strength, take the construction of national laboratories and the reorganization of national key laboratories as an opportunity to promote high-level scientific and technological innovation in the field of medical health, strengthen the construction of base platforms, and improve the hierarchical layout of the national medical scientific and technological innovation system; Building the National Institute of Medical Health and China Medical Health Hospital, reflecting the national will and undertaking the national mission, making them the core base and high-end strategic consulting think tank of national medical science and technology innovation, and providing support for improving the overall efficiency of national medical science and technology innovation; Pay attention to the high-level scientific and technological innovation of clinical medicine, pay attention to the cultivation of clinical medicine innovation ecosystem, and continuously enrich the resource pool of top medical scientists in China.

Wang Chen also said that China Academy of Medical Sciences will persist in facing people’s lives and health, make unremitting efforts in academic culture, institutional system, resource fund and international environment, create a fair, responsible, supportive, sustainable and dynamic ecological environment for medical science and technology innovation, promote the construction of a three-dimensional, multi-level, inclusive and cooperative national medical science and technology innovation system and core base, and strive to achieve good interaction with the international medical science and technology community, in order to achieve high-level medical science and technology self-reliance and support medical health.

Zhang Xuemin, a member of the Department of China Academy of Medical Sciences, believes that we should adhere to the correct value orientation and establish the evaluation of outstanding medical science and technology innovation, that is, what have we discovered and invented? What’s the point? Is it true and reliable? The evaluation of scientific and technological personnel should build an evaluation system that is based on "representative works", attaches importance to original innovation and major scientific discoveries, and reflects the country’s major strategic needs, breaks the scientific research routine, realizes the innovation paradigm, promotes mission-driven and interest-driven scientific and technological research with excellent scientific ecology and culture, promotes valuable, true and reliable scientific and technological innovation facing the world’s scientific and technological frontier, and promotes the development of national medical and health undertakings.

Liu Depei, a member of China Academy of Medical Sciences, believes that the core of the framework of medical science and technology innovation system is innovation elements, infrastructure, value creation and institutional environment. The layout of medical science and technology innovation system should make great efforts to promote the innovation of basic theory, the development of biomedical industry, realize the self-reliance of science and technology and improve the level of clinical diagnosis and treatment. National key laboratories, scientific research institutes, medical universities, pharmaceutical enterprises and medical institutions should cooperate with each other and combine their respective advantages to become types of subjects that play different roles. With the support of infrastructure and innovative elements, change the number of base construction, tilt the layout to clinic, coordinate the development of education, science and technology and talent elements, build basic and strategic support, and increase the investment of funds and personnel; With the high-efficiency collaborative medical science and technology innovation network, the multi-agent integrated medical science and technology innovation model is constructed, and the road of medical innovation is opened with system construction as the core, which stimulates the vitality of the main body and enhances the innovation efficiency.

Dong Erdan, a member of China Academy of Medical Sciences, believes that medical science and technology innovation has the characteristics of high risk, high public investment, inherent ethical problems and strict supervision. Therefore, we should adhere to the principle of free exploration and demand-oriented, optimize the structure and layout of medical scientific research in China, take the burden of disease and social demand as traction, solve outstanding scientific problems as driving force, and combine big data analysis to further optimize the allocation and management of medical research resources and promote the formation of a good ecological environment for medical scientific and technological innovation.

Member Wang Xiaofan, member of the Department of China Academy of Medical Sciences, pointed out that developing high-level medical science and technology is the key to building a high-level medical health cause, and it is also a hot field of international science and technology frontier competition and cooperation. In recent years, the international cooperation in medical health in China is increasing day by day, which is helpful to solve the research problems faced by biomedical research. Member Wang Xiaofan suggested further promoting international cooperation with universities, research institutes and academic groups as the main body, helping young scientists to establish more international cooperative relations, taking the lead in organizing global research projects or big science plans, taking China as the main venue, attracting global researchers to jointly study, and providing more China wisdom and Chinese programs for the development of human health.

China Medical Development Conference is an annual platform for China medical circles to discuss and plan the national medical development. Its purpose and function are to unite the national medical science and technology development ideas, lead the national medical science and technology development direction, display the important achievements of China medical science and technology, promote the national medical and health education reform, and promote the high-quality development of the national medical and health undertakings. The annual conference was held on the third weekend of April of that year, and the first conference was held in 2021, which has been held for three times so far.